Glutamine Metabolism: Molecular Regulation, Biological Functions, and Diseases

Abstract

Glutaminolysis, the metabolic process of converting glutamine into key intermediates, plays an essential role in cellular energy production, signaling, biosynthesis, and redox balance. Deregulation of glutamine metabolism significantly influences various pathological conditions, including cancers and metabolic and neurological diseases. Emerging evidence shows that long noncoding RNAs (lncRNAs), circular RNAs (circRNAs), and oncogenic alterations in glutamine transporters and enzymes enhance glutamine's role as an alternative energy source, supporting cell survival and proliferation under nutrient and oxygen deprivation conditions. To combat the pathogenic effects of altered glutamine metabolism, researchers are developing targeted inhibitors of key enzymes and transporters involved in glutaminolysis. By interfering with the mechanisms that support the growth of cancer cells, these inhibitors may be able to stop the growth of tumors and treat metabolic and neurological conditions. This review provides a comprehensive overview of existing inhibitors and ongoing clinical trials targeting glutamine metabolism, focusing on its potential as a cancer therapeutic strategy. Additionally, the role of lncRNAs and circRNAs in regulating glutamine metabolism is explored, revealing novel avenues for therapeutic intervention in cancer and other diseases.

Keywords

cancer / circular RNAs / glutaminolysis / glutamine metabolism / long noncoding RNAs / therapeutic targeting

References

[1] N. N. Pavlova, J. Zhu, and C. B. Thompson, “The Hallmarks of Cancer Metabolism: Still Emerging,” Cell Metabolism 34, no. 3 (2022): 355-377.

[2] Z. D. Xiao, L. Zhuang, and B. Gan, “Long Non-Coding RNAs in Cancer Metabolism,” BioEssays: News and Reviews in Molecular, Cellular and Developmental Biology 38, no. 10 (2016): 991-996.

[3] R. J. Deberardinis, N. Sayed, D. Ditsworth, and C. B. Thompson, “Brick By Brick: Metabolism and Tumor Cell Growth,” Current Opinion in Genetics & Development 18, no. 1 (2008): 54-61.

[4] M. G. Vander Heiden, L. C. Cantley, and C. B. Thompson, “Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation,” Science 324, no. 5930 (2009): 1029-1033.

[5] N. N. Pavlova and C. B. Thompson, “The Emerging Hallmarks of Cancer Metabolism,” Cell Metabolism 23, no. 1 (2016): 27-47.

[6] R. J. DeBerardinis and T. Cheng, “Q's Next: The Diverse Functions of Glutamine in Metabolism, Cell Biology and Cancer,” Oncogene 29, no. 3 (2010): 313-324.

[7] J. M. Matés, J. A. Segura, J. A. Campos-Sandoval, et al., “Glutamine Homeostasis and Mitochondrial Dynamics,” The International Journal of Biochemistry & Cell Biology 41, no. 10 (2009): 2051-2061.

[8] C. T. Hensley, A. T. Wasti, and R. J. DeBerardinis, “Glutamine and Cancer: Cell Biology, Physiology, and Clinical Opportunities,” The Journal of Clinical Investigation 123, no. 9 (2013): 3678-3684.

[9] B. J. Altman, Z. E. Stine, and C. V. Dang, “From Krebs to Clinic: Glutamine Metabolism to Cancer Therapy,” Nature Reviews Cancer 16, no. 10 (2016): 619-634.

[10] Y. Zhao, E. B. Butler, and M. Tan, “Targeting Cellular Metabolism to Improve Cancer Therapeutics,” Cell Death & Disease 4, no. 3 (2013): e532.

[11] L. Yang, S. Venneti, and D. Nagrath, “Glutaminolysis: A Hallmark of Cancer Metabolism,” Annual Review of Biomedical Engineering 19 (2017): 163-194.

[12] D. Gaglio, C. M. Metallo, P. A. Gameiro, et al., “Oncogenic K-Ras Decouples Glucose and Glutamine Metabolism to Support Cancer Cell Growth,” Molecular Systems Biology 7 (2011): 523.

[13] N. S. Chandel, “Mitochondria and Cancer,” Cancer & Metabolism 2 (2014): 8.

[14] M. A. Medina, “Glutamine and Cancer,” The Journal of Nutrition 131 (2001). Suppl.

[15] L. J. Reitzer, B. M. Wice, and D. Kennell, “Evidence That Glutamine, Not Sugar, is the Major Energy Source for Cultured HeLa Cells,” The Journal of Biological Chemistry 254, no. 8 (1979): 2669-2676.

[16] W. Lu, H. Pelicano, and P. Huang, “Cancer Metabolism: Is Glutamine Sweeter Than Glucose?,” Cancer Cell 18, no. 3 (2010): 199-200.

[17] R. V. Durán, W. Oppliger, A. M. Robitaille, et al., “Glutaminolysis Activates Rag-mTORC1 Signaling,” Molecular Cell 47, no. 3 (2012): 349-358.

[18] L. Jin, D. Li, G. N. Alesi, et al., “Glutamate Dehydrogenase 1 Signals Through Antioxidant Glutathione Peroxidase 1 to Regulate Redox Homeostasis and Tumor Growth,” Cancer Cell 27, no. 2 (2015): 257-270.

[19] J. Zhang, J. Fan, S. Venneti, et al., “Asparagine Plays a Critical Role in Regulating Cellular Adaptation to Glutamine Depletion,” Molecular Cell 56, no. 2 (2014): 205-218.

[20] C. H. Eng, K. Yu, J. Lucas, E. White, and R. T. Abraham, “Ammonia Derived From Glutaminolysis Is a Diffusible Regulator of Autophagy,” Science Signaling 3, no. 119 (2010): ra31.

[21] W. Liu, A. Le, C. Hancock, et al., “Reprogramming of Proline and Glutamine Metabolism Contributes to the Proliferative and Metabolic Responses Regulated by Oncogenic Transcription Factor c-MYC,” Proceedings of the National Academy of Sciences of the United States of America 109, no. 23 (2012): 8983-8988.

[22] A. Le, A. N. Lane, M. Hamaker, et al., “Glucose-independent Glutamine Metabolism via TCA Cycling for Proliferation and Survival in B Cells,” Cell Metabolism 15, no. 1 (2012): 110-121.

[23] Y. E. Moreira Franco, M. J. Alves, M. Uno, et al., “Glutaminolysis Dynamics During Astrocytoma Progression Correlates with Tumor Aggressiveness,” Cancer & Metabolism 9, no. 1 (2021): 18.

[24] A. J. Bott, I. C. Peng, Y. Fan, et al., “Oncogenic Myc Induces Expression of Glutamine Synthetase Through Promoter Demethylation,” Cell Metabolism 22, no. 6 (2015): 1068-1077.

[25] J. Zou, K. Du, S. Li, et al., “Glutamine Metabolism Regulators Associated With Cancer Development and the Tumor Microenvironment: A Pan-Cancer Multi-Omics Analysis,” Genes 12, no. 9 (2021).

[26] M. Laplante and D. M. Sabatini, “mTOR Signaling in Growth Control and Disease,” Cell 149, no. 2 (2012): 274-293.

[27] P. Nicklin, P. Bergman, B. Zhang, et al., “Bidirectional Transport of Amino Acids Regulates mTOR and Autophagy,” Cell 136, no. 3 (2009): 521-534.

[28] J. E. Ziello, I. S. Jovin, and Y. Huang, “Hypoxia-Inducible Factor (HIF)-1 Regulatory Pathway and Its Potential for Therapeutic Intervention in Malignancy and Ischemia,” The Yale Journal of Biology and Medicine 80, no. 2 (2007): 51-60.

[29] Y. H. Cha, J. I. Yook, H. S. Kim, and N. H. Kim, “Catabolic Metabolism During Cancer EMT,” Archives of Pharmacal Research 38, no. 3 (2015): 313-320.

[30] O. Dumortier, C. Hinault, and E. Van Obberghen, “MicroRNAs and Metabolism Crosstalk in Energy Homeostasis,” Cell Metabolism 18, no. 3 (2013): 312-324.

[31] T. Gutschner and S. Diederichs, “The Hallmarks of Cancer: A Long Non-coding RNA Point of View,” RNA Biology 9, no. 6 (2012): 703-719.

[32] T. Yu, Y. Wang, Y. Fan, et al., “CircRNAs in Cancer Metabolism: A Review,” Journal of Hematology & Oncology 12, no. 1 (2019): 90.

[33] F. Yang, H. Zhang, Y. Mei, and M. Wu, “Reciprocal Regulation of HIF-1α and lincRNA-p21 Modulates the Warburg Effect,” Molecular Cell 53, no. 1 (2014): 88-100.

[34] C. L. Hung, L. Y. Wang, Y. L. Yu, et al., “A Long Noncoding RNA Connects c-Myc to Tumor Metabolism,” Proceedings of the National Academy of Sciences of the United States of America 111, no. 52 (2014): 18697-18702.

[35] Y. Cai, B. Tian, Y. Deng, et al., “Glutamine Metabolism Promotes Renal Fibrosis Through Regulation of Mitochondrial Energy Generation and Mitochondrial Fission,” International Journal of Biological Sciences 20, no. 3 (2024): 987-1003.

[36] J. Hu, Z. Zhang, H. Hu, et al., “LRH-1 Activation Alleviates Diabetes-induced Podocyte Injury by Promoting GLS2-mediated Glutaminolysis,” Cell Proliferation 56, no. 11 (2023): e13479.

[37] R. Bornstein, M. T. Mulholland, M. Sedensky, P. Morgan, and S. C. Johnson, “Glutamine Metabolism in Diseases Associated With Mitochondrial Dysfunction,” Molecular and Cellular Neuroscience 126 (2023): 103887.

[38] E. Roth, “Nonnutritive Effects of Glutamine,” The Journal of Nutrition 138, no. 10 (2008): 2031s.

[39] M. O. Johnson, M. M. Wolf, M. Z. Madden, et al. Distinct Regulation of Th17 and Th1 Cell Differentiation by Glutaminase-Dependent Metabolism. Cell 175, no. 7 (2018): 1780-1795.e1719.

[40] P. Newsholme, “Why is L-glutamine Metabolism Important to Cells of the Immune System in Health, Postinjury, Surgery or Infection?,” The Journal of Nutrition 131 (2001). Suppl.

[41] W. Durante, “The Emerging Role of L-Glutamine in Cardiovascular Health and Disease,” Nutrients 11, no. 9 (2019).

[42] D. Bano, K. W. Young, C. J. Guerin, et al., “Cleavage of the Plasma Membrane Na+/Ca2+ Exchanger in Excitotoxicity,” Cell 120, no. 2 (2005): 275-285.

[43] C. L. Lin, Q. Kong, G. D. Cuny, and M. A. Glicksman, “Glutamate Transporter EAAT2: A New Target for the Treatment of Neurodegenerative Diseases,” Future Medicinal Chemistry 4, no. 13 (2012): 1689-1700.

[44] P. Maher, K. van Leyen, P. N. Dey, B. Honrath, A. Dolga, and A. Methner, “The Role of Ca(2+) in Cell Death Caused by Oxidative Glutamate Toxicity and Ferroptosis,” Cell Calcium 70 (2018): 47-55.

[45] J. Lewerenz and P. Maher, “Chronic Glutamate Toxicity in Neurodegenerative Diseases—What Is the Evidence?,” Frontiers in Neuroscience 9 (2015): 469.

[46] I. D. Weiner and L. L. Hamm. Molecular Mechanisms of Renal Ammonia Transport. Annual Review of Physiology 69 (2007): 317-340.

[47] M. H. Kim and H. Kim, “Oncogenes and Tumor Suppressors Regulate Glutamine Metabolism in Cancer Cells,” Journal of Cancer Prevention 18, no. 3 (2013): 221-226.

[48] M. Yamamoto, H. Inohara, and T. Nakagawa, “Targeting Metabolic Pathways for Head and Neck Cancers Therapeutics,” Cancer Metastasis Reviews 36, no. 3 (2017): 503-514.

[49] J. Son, C. A. Lyssiotis, H. Ying, et al., “Glutamine Supports Pancreatic Cancer Growth Through a KRAS-Regulated Metabolic Pathway,” Nature 496, no. 7443 (2013): 101-105.

[50] D. R. Wise, R. J. DeBerardinis, A. Mancuso, et al., “Myc Regulates a Transcriptional Program that Stimulates Mitochondrial Glutaminolysis and Leads to Glutamine Addiction,” Proceedings of the National Academy of Sciences of the United States of America 105, no. 48 (2008): 18782-18787.

[51] S. Qie, A. Yoshida, S. Parnham, et al., “Targeting Glutamine-Addiction and Overcoming CDK4/6 Inhibitor Resistance in human Esophageal Squamous Cell Carcinoma,” Nature Communications 10, no. 1 (2019): 1296.

[52] P. Gao, I. Tchernyshyov, T. C. Chang, et al., “c-Myc Suppression of miR-23a/b Enhances Mitochondrial Glutaminase Expression and Glutamine Metabolism,” Nature 458, no. 7239 (2009): 762-765.

[53] A. Csibi, G. Lee, S.-O. Yoon, et al., “The mTORC1/S6K1 Pathway Regulates Glutamine Metabolism Through the eIF4B-Dependent Control of c-Myc Translation,” Current Biology 24, no. 19 (2014): 2274-2280.

[54] S. J. Zacharek, Y. Xiong, and S. D. Shumway, “Negative Regulation of TSC1-TSC2 by Mammalian D-type Cyclins,” Cancer Research 65, no. 24 (2005): 11354-11360.

[55] S. Goel, Q. Wang, A. C. Watt, et al., “Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers With CDK4/6 Inhibitors,” Cancer Cell 29, no. 3 (2016): 255-269.

[56] D. Cui, R. Qu, D. Liu, X. Xiong, T. Liang, and Y. Zhao, “The Cross Talk between p53 and mTOR Pathways in Response to Physiological and Genotoxic Stresses,” Frontiers in Cell and Developmental Biology 9 (2021): 775507.

[57] W. Hu, C. Zhang, R. Wu, Y. Sun, A. Levine, and Z. Feng, “Glutaminase 2, a Novel p53 Target Gene Regulating Energy Metabolism and Antioxidant Function,” Proceedings of the National Academy of Sciences of the United States of America 107, no. 16 (2010): 7455-7460.

[58] S. Matoba, J. G. Kang, W. D. Patino, et al., “p53 Regulates Mitochondrial Respiration,” Science 312, no. 5780 (2006): 1650-1653.

[59] D. Yu, X. Shi, G. Meng, et al., “Kidney-Type Glutaminase (GLS1) is a Biomarker for Pathologic Diagnosis and Prognosis of Hepatocellular Carcinoma,” Oncotarget 6, no. 10 (2015): 7619-7631.

[60] R. Liu, Y. Li, L. Tian, et al., “Gankyrin Drives Metabolic Reprogramming to Promote Tumorigenesis, Metastasis and Drug Resistance Through Activating β-catenin/c-Myc Signaling in human Hepatocellular Carcinoma,” Cancer Letters 443 (2019): 34-46.

[61] M. O. Yuneva, T. W. Fan, T. D. Allen, et al., “The Metabolic Profile of Tumors Depends on both the Responsible Genetic Lesion and Tissue Type,” Cell Metabolism 15, no. 2 (2012): 157-170.

[62] C. V. Dang, J. W. Kim, P. Gao, and J. Yustein, “The Interplay Between MYC and HIF in Cancer,” Nature Reviews Cancer 8, no. 1 (2008): 51-56.

[63] H. Hu, N. Takano, L. Xiang, D. M. Gilkes, W. Luo, and G. L. Semenza, “Hypoxia-Inducible Factors Enhance Glutamate Signaling in Cancer Cells,” Oncotarget 5, no. 19 (2014): 8853-8868.

[64] L. Xiang, J. Mou, B. Shao, et al., “Glutaminase 1 Expression in Colorectal Cancer Cells is Induced by Hypoxia and Required for Tumor Growth, Invasion, and Metastatic Colonization,” Cell Death & Disease 10, no. 2 (2019): 40.

[65] M. Ohh, C. W. Park, M. Ivan, et al., “Ubiquitination of Hypoxia-Inducible Factor Requires Direct Binding to the Beta-Domain of the von Hippel-Lindau Protein,” Nature Cell Biology 2, no. 7 (2000): 423-427.

[66] A. L. Cohen, S. L. Holmen, and H. Colman, “IDH1 and IDH2 Mutations in Gliomas,” Current Neurology and Neuroscience Reports 13, no. 5 (2013): 345.

[67] A. S. McKenney and R. L. Levine, “Isocitrate Dehydrogenase Mutations in Leukemia,” The Journal of Clinical Investigation 123, no. 9 (2013): 3672-3677.

[68] L. Dang, S. Jin, and S. M. Su, “IDH Mutations in Glioma and Acute Myeloid Leukemia,” Trends in Molecular Medicine 16, no. 9 (2010): 387-397.

[69] H. Yang, D. Ye, K. L. Guan, and Y Xiong, “IDH1 and IDH2 Mutations in Tumorigenesis: Mechanistic Insights and Clinical Perspectives,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 18, no. 20 (2012): 5562-5571.

[70] S. Gross, R. A. Cairns, M. D. Minden, et al., “Cancer-associated Metabolite 2-hydroxyglutarate Accumulates in Acute Myelogenous Leukemia With Isocitrate Dehydrogenase 1 and 2 Mutations,” The Journal of Experimental Medicine 207, no. 2 (2010): 339-344.

[71] L. Dang, D. W. White, S. Gross, et al., “Cancer-associated IDH1 Mutations Produce 2-hydroxyglutarate,” Nature 462, no. 7274 (2009): 739-744.

[72] P. S. Ward, J. Patel, D. R. Wise, et al., “The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations is a Neomorphic Enzyme Activity Converting Alpha-ketoglutarate to 2-Hydroxyglutarate,” Cancer Cell 17, no. 3 (2010): 225-234.

[73] M. A. Selak, S. M. Armour, E. D. MacKenzie, et al., “Succinate Links TCA Cycle Dysfunction to Oncogenesis by Inhibiting HIF-alpha Prolyl Hydroxylase,” Cancer Cell 7, no. 1 (2005): 77-85.

[74] P. Koivunen, S. Lee, C. G. Duncan, et al., “Transformation by the (R)-Enantiomer of 2-Hydroxyglutarate Linked to EGLN Activation,” Nature 483, no. 7390 (2012): 484-488.

[75] N. Masson and P. J. Ratcliffe, “Hypoxia Signaling Pathways in Cancer Metabolism: The Importance of Co-Selecting Interconnected Physiological Pathways,” Cancer & Metabolism 2, no. 1 (2014): 3.

[76] U. Martinez-Outschoorn, F. Sotgia, and M. P. Lisanti, “Tumor Microenvironment and Metabolic Synergy in Breast Cancers: Critical Importance of Mitochondrial Fuels and Function,” Seminars in Oncology 41, no. 2 (2014): 195-216.

[77] A. González, M. N. Hall, S. C. Lin, and D. G. Hardie, “AMPK and TOR: The Yin and Yang of Cellular Nutrient Sensing and Growth Control,” Cell Metabolism 31, no. 3 (2020): 472-492.

[78] V. H. Villar, T. L. Nguyen, V. Delcroix, et al., “mTORC1 inhibition in Cancer Cells Protects From Glutaminolysis-mediated Apoptosis During Nutrient Limitation,” Nature Communications 8 (2017): 14124.

[79] V. H. Villar, T. L. Nguyen, S. Terés, C. Bodineau, and R. V. Durán, “Escaping mTOR Inhibition for Cancer Therapy: Tumor Suppressor Functions of mTOR,” Molecular & Cellular Oncology 4, no. 3 (2017): e1297284.

[80] C. Bodineau, M. Tomé, S. Courtois, et al., “Two Parallel Pathways Connect Glutamine Metabolism and mTORC1 Activity to Regulate Glutamoptosis,” Nature Communications 12, no. 1 (2021): 4814.

[81] V. J. Thannickal and J. C. Horowitz, “Evolving Concepts of Apoptosis in Idiopathic Pulmonary Fibrosis,” Proceedings of the American Thoracic Society 3, no. 4 (2006): 350-356.

[82] F. Drakopanagiotakis, A. Xifteri, V. Polychronopoulos, and D. Bouros, “Apoptosis in Lung Injury and Fibrosis,” The European Respiratory Journal 32, no. 6 (2008): 1631-1638.

[83] L. Bai, K. Bernard, X. Tang, et al., “Glutaminolysis Epigenetically Regulates Antiapoptotic Gene Expression in Idiopathic Pulmonary Fibrosis Fibroblasts,” American Journal of Respiratory Cell and Molecular Biology 60, no. 1 (2019): 49-57.

[84] C. M. Niswender and P. J. Conn, “Metabotropic Glutamate Receptors: Physiology, Pharmacology, and Disease,” Annual Review of Pharmacology and Toxicology 50 (2010): 295-322.

[85] A. Arcella, G. Carpinelli, G. Battaglia, et al., “Pharmacological Blockade of Group II Metabotropic Glutamate Receptors Reduces the Growth of Glioma Cells in Vivo,” Neuro-oncology 7, no. 3 (2005): 236-245.

[86] C. Ciceroni, M. Bonelli, E. Mastrantoni, et al., “Type-3 Metabotropic Glutamate Receptors Regulate Chemoresistance in Glioma Stem Cells, and Their Levels Are Inversely Related to Survival in Patients With Malignant Gliomas,” Cell Death and Differentiation 20, no. 3 (2013): 396-407.

[87] J. L. Teh, R. Shah, et al., “Metabotropic Glutamate Receptor 1 Disrupts Mammary Acinar Architecture and Initiates Malignant Transformation of Mammary Epithelial Cells,” Breast Cancer Research and Treatment 151, no. 1 (2015): 57-73.

[88] J. L. Teh and S. Chen, “Glutamatergic Signaling in Cellular Transformation,” Pigment Cell & Melanoma Research 25, no. 3 (2012): 331-342.

[89] T. D. Prickett, X. Wei, I. Cardenas-Navia, et al., “Exon Capture Analysis of G Protein-Coupled Receptors Identifies Activating Mutations in GRM3 in Melanoma,” Nature Genetics 43, no. 11 (2011): 1119-1126.

[90] E. Dornier, N. Rabas, L. Mitchell, et al., “Glutaminolysis Drives Membrane Trafficking to Promote Invasiveness of Breast Cancer Cells,” Nature Communications 8, no. 1 (2017): 2255.

[91] Y. Hao, Y. Samuels, Q. Li, et al., “Oncogenic PIK3CA Mutations Reprogram Glutamine Metabolism in Colorectal Cancer,” Nature Communications 7 (2016): 11971.

[92] B. Smith, X. L. Schafer, A. Ambeskovic, C. M. Spencer, H. Land, and J. Munger, “Addiction to Coupling of the Warburg Effect With Glutamine Catabolism in Cancer Cells,” Cell Reports 17, no. 3 (2016): 821-836.

[93] C. C. Wong, Y. Qian, X. Li, et al., “SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells with KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate,” Gastroenterology 151, no. 5 (2016): 946.

[94] K. N. Papanicolaou, B. O'Rourke, and D. B. Foster, “Metabolism Leaves its Mark on the Powerhouse: Recent Progress in Post-Translational Modifications of Lysine in Mitochondria,” Frontiers in Physiology 5 (2014): 301.

[95] S. Zhao, W. Xu, W. Jiang, et al., “Regulation of Cellular Metabolism by Protein Lysine Acetylation,” Science 327, no. 5968 (2010): 1000-1004.

[96] J. Du, Y. Zhou, X. Su, et al., “Sirt5 is a NAD-Dependent Protein Lysine Demalonylase and Desuccinylase,” Science 334, no. 6057 (2011): 806-809.

[97] M. J. Rardin, W. He, Y. Nishida, et al., “SIRT5 Regulates the Mitochondrial Lysine Succinylome and Metabolic Networks,” Cell Metabolism 18, no. 6 (2013): 920-933.

[98] J. Park, Y. Chen, D. X. Tishkoff, et al., “SIRT5-Mediated Lysine Desuccinylation Impacts Diverse Metabolic Pathways,” Molecular Cell 50, no. 6 (2013): 919-930.

[99] Y. Nishida, M. J. Rardin, C. Carrico, et al., “SIRT5 Regulates both Cytosolic and Mitochondrial Protein Malonylation with Glycolysis as a Major Target,” Molecular Cell 59, no. 2 (2015): 321-332.

[100] M. Tan, C. Peng, K. A. Anderson, et al., “Lysine Glutarylation is a Protein Posttranslational Modification Regulated by SIRT5,” Cell Metabolism 19, no. 4 (2014): 605-617.

[101] L. Zhou, F. Wang, R. Sun, et al., “SIRT5 promotes IDH2 Desuccinylation and G6PD Deglutarylation to Enhance Cellular Antioxidant Defense,” EMBO Reports 17, no. 6 (2016): 811-822.

[102] Y. Q. Wang, H. L. Wang, J. Xu, et al., “Sirtuin5 Contributes to Colorectal Carcinogenesis by Enhancing Glutaminolysis in a Deglutarylation-dependent Manner,” Nature Communications 9, no. 1 (2018): 545.

[103] A. K. Bauer, H. Y. Cho, L. Miller-Degraff, et al., “Targeted Deletion of Nrf2 Reduces Urethane-Induced Lung Tumor Development in Mice,” PLoS ONE 6, no. 10 (2011): e26590.

[104] G. M. DeNicola, F. A. Karreth, T. J. Humpton, et al., “Oncogene-Induced Nrf2 Transcription Promotes ROS Detoxification and Tumorigenesis,” Nature 475, no. 7354 (2011): 106-109.

[105] H. Satoh, T. Moriguchi, J. Takai, M. Ebina, and M. Yamamoto, “Nrf2 Prevents Initiation but Accelerates Progression Through the Kras Signaling Pathway During Lung Carcinogenesis,” Cancer Research 73, no. 13 (2013): 4158-4168.

[106] V. I. Sayin, M. X. Ibrahim, E. Larsson, J. A. Nilsson, P. Lindahl, and M. O. Bergo, “Antioxidants Accelerate Lung Cancer Progression in Mice,” Science Translational Medicine 6, no. 221 (2014).

[107] I. I. C. Chio, S. M. Jafarnejad, M. Ponz-Sarvise, et al., “NRF2 Promotes Tumor Maintenance by Modulating mRNA Translation in Pancreatic Cancer,” Cell 166, no. 4 (2016): 963-976.

[108] E. M. Kerr, E. Gaude, F. K. Turrell, C. Frezza, and C. P. Martins, “Mutant Kras Copy Number Defines Metabolic Reprogramming and Therapeutic Susceptibilities,” Nature 531, no. 7592 (2016): 110-113.

[109] Comprehensive Genomic Characterization of Squamous Cell Lung Cancers. Nature 489, no. 7417 (2012): 519-525.

[110] M. C. Jaramillo and D. D. Zhang, “The Emerging Role of the Nrf2-Keap1 Signaling Pathway in Cancer,” Genes & Development 27, no. 20 (2013): 2179-2191.

[111] P. A. Konstantinopoulos, D. Spentzos, E. Fountzilas, et al., “Keap1 Mutations and Nrf2 Pathway Activation in Epithelial Ovarian Cancer,” Cancer Research 71, no. 15 (2011): 5081-5089.

[112] T. Shibata, A. Kokubu, M. Gotoh, et al., “Genetic Alteration of Keap1 Confers Constitutive Nrf2 Activation and Resistance to Chemotherapy in Gallbladder Cancer,” Gastroenterology 135, no. 4 (1368): 1354.

[113] Y. Sato, T. Yoshizato, Y. Shiraishi, et al. “Integrated Molecular Analysis of Clear-Cell Renal Cell Carcinoma,” Nature Genetics 45, no. 8 (2013): 860-867.

[114] F. P. Fabrizio, M. Costantini, M. Copetti, et al., “Keap1/Nrf2 Pathway in Kidney Cancer: Frequent Methylation of KEAP1 Gene Promoter in Clear Renal Cell Carcinoma,” Oncotarget 8, no. 7 (2017): 11187-11198.

[115] L. A. Muscarella, R. Barbano, V. D'Angelo, et al., “Regulation of KEAP1 Expression by Promoter Methylation in Malignant Gliomas and Association With Patient's Outcome,” Epigenetics 6, no. 3 (2011): 317-325.

[116] E. Ramirez-Peña, J. Arnold, V. Shivakumar, et al., “The Epithelial to Mesenchymal Transition Promotes Glutamine Independence by Suppressing GLS2 Expression,” Cancers 11, no. 10 (2019).

[117] C. V. Dang, “MYC on the Path to Cancer,” Cell 149, no. 1 (2012): 22-35.

[118] D. Gaglio, C. Soldati, M. Vanoni, L. Alberghina, and F. Chiaradonna, “Glutamine Deprivation Induces Abortive s-Phase Rescued by Deoxyribonucleotides in k-ras Transformed Fibroblasts,” PLoS ONE 4, no. 3 (2009): e4715.

[119] B. Kalyanaraman, G. Cheng, M. Hardy, et al., “A Review of the Basics of Mitochondrial Bioenergetics, Metabolism, and Related Signaling Pathways in Cancer Cells: Therapeutic Targeting of Tumor Mitochondria With Lipophilic Cationic Compounds,” Redox Biology 14 (2018): 316-327.

[120] A. H. Berger, A. N. Brooks, X. Wu, et al., “High-Throughput Phenotyping of Lung Cancer Somatic Mutations,” Cancer Cell 30, no. 2 (2016): 214-228.

[121] A. Singh, V. Misra, R. K. Thimmulappa, et al., “Dysfunctional KEAP1-NRF2 Interaction in Non-Small-Cell Lung Cancer,” PLoS Medicine 3, no. 10 (2006): e420.

[122] A. Elgogary, Q. Xu, B. Poore, et al., “Combination Therapy with BPTES Nanoparticles and Metformin Targets the Metabolic Heterogeneity of Pancreatic Cancer,” Proceedings of the National Academy of Sciences of the United States of America 113, no. 36 (2016): E5328-5336.

[123] V. I. Sayin, S. E. LeBoeuf, S. X. Singh, et al., “Activation of the NRF2 Antioxidant Program Generates an Imbalance in central Carbon Metabolism in Cancer,” Elife 6 (2017).

[124] R. Romero, V. I. Sayin, S. M. Davidson, et al., “Keap1 Loss Promotes Kras-Driven Lung Cancer and Results in Dependence on Glutaminolysis,” Nature Medicine 23, no. 11 (2017): 1362-1368.

[125] A. K. Najumudeen, F. Ceteci, S. K. Fey, et al., “The Amino Acid Transporter SLC7A5 is Required for Efficient Growth of KRAS-Mutant Colorectal Cancer,” Nature Genetics 53, no. 1 (2021): 16-26.

[126] A. F. Ward, B. S. Braun, and K. M. Shannon, “Targeting Oncogenic Ras Signaling in Hematologic Malignancies,” Blood 120, no. 17 (2012): 3397-3406.

[127] S. Zhao, Y. Zhang, K. Sha, et al., “KRAS (G12D) Cooperates with AML1/ETO to Initiate a Mouse Model Mimicking human Acute Myeloid Leukemia,” Cellular Physiology and Biochemistry: International Journal of Experimental Cellular Physiology, biochemistry, and pharmacology 33, no. 1 (2014): 78-87.

[128] C. C. Wong, J. Xu, X. Bian, et al., “In Colorectal Cancer Cells with Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance,” Gastroenterology 159, no. 6 (2020): 2163-2180.

[129] R. Leidner, N. Sanjuan Silva, H. Huang, et al., “Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer,” The New England Journal of Medicine 386, no. 22 (2022): 2112-2119.

[130] E. Zorde Khvalevsky, R. Gabai, I. H. Rachmut, et al., “Mutant KRAS is a Druggable Target for Pancreatic Cancer,” Proceedings of the National Academy of Sciences of the United States of America 110, no. 51 (2013): 20723-20728.

[131] C. S. Verissimo, R. M. Overmeer, B. Ponsioen, et al., “Targeting Mutant RAS in Patient-derived Colorectal Cancer Organoids by Combinatorial Drug Screening,” Elife 5 (2016).

[132] C. X. Wang, T. T. Wang, K. D. Zhang, et al., “Pan-KRAS Inhibitors Suppress Proliferation Through Feedback Regulation in Pancreatic Ductal Adenocarcinoma,” Acta Pharmacologica Sinica (2022).

[133] L. Huang, Z. Guo, F. Wang, and L. Fu, “KRAS Mutation: From Undruggable to Druggable in Cancer,” Signal Transduction and Targeted Therapy 6, no. 1 (2021): 386.

[134] T. Hulf, P. Bellosta, M. Furrer, et al., “Whole-genome Analysis Reveals a Strong Positional Bias of Conserved dMyc-Dependent E-boxes,” Molecular and Cellular Biology 25, no. 9 (2005): 3401-3410.

[135] M. Hartl, “The Quest for Targets Executing MYC-Dependent Cell Transformation,” Frontiers in Oncology 6 (2016): 132.

[136] H. Chen, H. Liu, and G. Qing, “Targeting Oncogenic Myc as a Strategy for Cancer Treatment,” Signal Transduction and Targeted Therapy 3 (2018): 5.

[137] M. Martín-Rufián, R. Nascimento-Gomes, A. Higuero, et al., “Both GLS Silencing and GLS2 Overexpression Synergize with Oxidative Stress Against Proliferation of Glioma Cells,” Journal of Molecular Medicine 92, no. 3 (2014): 277-290.

[138] R. Wang, C. P. Dillon, L. Z. Shi, et al., “The Transcription Factor Myc Controls Metabolic Reprogramming Upon T Lymphocyte Activation,” Immunity 35, no. 6 (2011): 871-882.

[139] Z. Wang, Q. Jiang, and C. Dong, “Metabolic Reprogramming in Triple-negative Breast Cancer,” Cancer Biology & Medicine 17, no. 1 (2020): 44-59.

[140] D. Nowis, A. Malenda, K. Furs, et al., “Statins Impair Glucose Uptake in human Cells,” BMJ Open Diabetes Research & Care 2, no. 1 (2014): e000017.

[141] W. W. Souba, “Glutamine and Cancer,” Annals of Surgery 218, no. 6 (1993): 715-728.

[142] R. V. Durán and M. N. Hall, “Glutaminolysis Feeds mTORC1,” Cell Cycle (Georgetown, Tex) 11, no. 22 (2012): 4107-4108.

[143] R. V. Durán, E. D. MacKenzie, H. Boulahbel, et al., “HIF-Independent Role of Prolyl Hydroxylases in the Cellular Response to Amino Acids,” Oncogene 32, no. 38 (2013): 4549-4556.

[144] C. G. Proud, X. Wang, J. V. Patel, et al., “Interplay Between Insulin and Nutrients in the Regulation of Translation Factors,” Biochemical Society Transactions 29 (2001): 541-547.

[145] R. C. Russell, H. X. Yuan, and K. L. Guan, “Autophagy Regulation by Nutrient Signaling,” Cell Research 24, no. 1 (2014): 42-57.

[146] K. E. van der Vos, P. Eliasson, T. Proikas-Cezanne, et al., “Modulation of Glutamine Metabolism by the PI(3)K-PKB-FOXO Network Regulates Autophagy,” Nature Cell Biology 14, no. 8 (2012): 829-837.

[147] K. E. van der Vos and P. J. Coffer, “Glutamine Metabolism Links Growth Factor Signaling to the Regulation of Autophagy,” Autophagy 8, no. 12 (2012): 1862-1864.

[148] V. H. Villar, F. Merhi, M. Djavaheri-Mergny, and R. V. Durán, “Glutaminolysis and Autophagy in Cancer,” Autophagy 11, no. 8 (2015): 1198-1208.

[149] A. Lagunas-Martínez, V. Madrid-Marina, C. Gómez-Cerón, J. Deas, and O. Peralta-Zaragoza, “The Autophagy Process in Cervical Carcinogenesis: Role of Non-Coding-RNAs, Molecular Mechanisms, and Therapeutic Targets,” Cells 11, no. 8 (2022).

[150] T. Y. Fung, A. Iyaswamy, S. G. Sreenivasmurthy, et al., “Klotho an Autophagy Stimulator as a Potential Therapeutic Target for Alzheimer's Disease: A Review,” Biomedicines 10, no. 3 (2022).

[151] T. Zhu, H. Zhang, S. Li, K. Wu, Y. Yin, and X. Zhang, “Detoxified Pneumolysin Derivative ΔA146Ply Inhibits Autophagy and Induces Apoptosis in Acute Myeloid Leukemia Cells by Activating mTOR Signaling,” Experimental & Molecular Medicine 54, no. 5 (2022): 601-612.

[152] W. Li, Y. Li, Y. Guan, et al., “TNFAIP8L2/TIPE2 impairs Autolysosome Reformation via Modulating the RAC1-MTORC1 Axis,” Autophagy 17, no. 6 (2021): 1410-1425.

[153] Z. Jiang, J. A. Jacob, D. S. Loganathachetti, P. Nainangu, and C. B. β-Elemene, “Mechanistic Studies on Cancer Cell Interaction and its Chemosensitization Effect,” Frontiers in Pharmacology 8 (2017): 105.

[154] K. Zou, E. Tong, Y. Xu, X. Deng, and L. Zou, “Down Regulation of Mammalian Target of Rapamycin Decreases HIF-1α and Survivin Expression in Anoxic Lung Adenocarcinoma A549 Cell to Elemene and/or Irradiation,” Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine 35, no. 10 (2014): 9735-9741.

[155] J. Liu, Y. Zhang, J. Qu, et al., “β-Elemene-Induced Autophagy Protects Human Gastric Cancer Cells from Undergoing Apoptosis,” BMC cancer 11 (2011): 183.

[156] K. Jiang, H. Chen, K. Tang, et al., “Puerarin Inhibits Bladder Cancer Cell Proliferation Through the mTOR/p70S6K Signaling Pathway,” Oncology Letters 15, no. 1 (2018): 167-174.

[157] K. W. Lu, M. L. Tsai, J. C. Chen, et al., “Gypenosides Inhibited Invasion and Migration of human Tongue Cancer SCC4 Cells Through Down-regulation of NFkappaB and Matrix Metalloproteinase-9,” Anticancer Research 28, no. 2a (2008): 1093-1099.

[158] V. H. Villar and R. V. Durán, “Glutamoptosis: A New Cell Death Mechanism Inhibited by Autophagy During Nutritional Imbalance,” Autophagy 13, no. 6 (2017): 1078-1079.

[159] N. Bushati and S. M. Cohen, “microRNA Functions,” Annual Review of Cell and Developmental Biology 23 (2007): 175-205.

[160] B. Chen, H. Li, X. Zeng, et al., “Roles of microRNA on Cancer Cell Metabolism,” Journal of Translational Medicine 10 (2012): 228.

[161] W. Yan, X. Wu, W. Zhou, et al., “Cancer-cell-secreted Exosomal miR-105 Promotes Tumour Growth Through the MYC-dependent Metabolic Reprogramming of Stromal Cells,” Nature Cell Biology 20, no. 5 (2018): 597-609.

[162] J. Wang, B. Wang, H. Ren, and W. Chen, “miR-9-5p Inhibits Pancreatic Cancer Cell Proliferation, Invasion and Glutamine Metabolism by Targeting GOT1,” Biochemical and Biophysical Research Communications 509, no. 1 (2019): 241-248.

[163] B. Anderton, R. Camarda, S. Balakrishnan, et al., “MYC-Driven Inhibition of the Glutamate-Cysteine Ligase Promotes Glutathione Depletion in Liver Cancer,” EMBO Reports 18, no. 4 (2017): 569-585.

[164] J. Li, X. Li, L. Wu, M. Pei, H. Li, and Y. Jiang, “miR-145 Inhibits Glutamine Metabolism Through c-myc/GLS1 Pathways in Ovarian Cancer Cells,” Cell Biology International 43, no. 8 (2019): 921-930.

[165] X. Chang, W. Zhu, H. Zhang, and S. Lian, “Sensitization of Melanoma Cells to Temozolomide by Overexpression of microRNA 203 Through Direct Targeting of Glutaminase-mediated Glutamine Metabolism,” Clinical and Experimental Dermatology 42, no. 6 (2017): 614-621.

[166] Z. Liu, J. Wang, Y. Li, J. Fan, L. Chen, and R. Xu, “MicroRNA-153 Regulates Glutamine Metabolism in Glioblastoma Through Targeting Glutaminase,” Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine 39, no. 2 (2017): 1010428317691429.

[167] J. Dong, D. Xiao, Z. Zhao, et al., “Epigenetic Silencing of microRNA-137 Enhances ASCT2 Expression and Tumor Glutamine Metabolism,” Oncogenesis 6, no. 7 (2017): e356.

[168] D. Sengupta, T. Cassel, K. Y. Teng, et al., “Regulation of Hepatic Glutamine Metabolism by miR-122,” Molecular Metabolism 34 (2020): 174-186.

[169] J. Zhang, L. Wang, S. Mao, et al., “miR-1-3p Contributes to Cell Proliferation and Invasion by Targeting Glutaminase in Bladder Cancer Cells,” Cellular Physiology and Biochemistry: International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology 51, no. 2 (2018): 513-527.

[170] B. R. Muys, J. F. Sousa, J. R. Plaça, et al., “miR-450a Acts as a Tumor Suppressor in Ovarian Cancer by Regulating Energy Metabolism,” Cancer Research 79, no. 13 (2019): 3294-3305.

[171] R. Zhang, J. C. Zhu, H. Hu, Q. Y. Lin, W. Shao, and T. H. Ji, “MicroRNA-140-5p Suppresses Invasion and Proliferation of Glioma Cells by Targeting Glutamate-ammonia Ligase (GLUL),” Neoplasma 67, no. 2 (2020): 371-378.

[172] X. Zhang, Z. Li, Z. Xuan, et al., “Retraction Note: Novel Role of miR-133a-3p in Repressing Gastric Cancer Growth and Metastasis via Blocking Autophagy-mediated Glutaminolysis,” Journal of Experimental & Clinical Cancer Research: CR 43, no. 1 (2024): 197.

[173] R. Kaur, S. Kanthaje, S. Taneja, R. K. Dhiman, and A. Chakraborti, “miR-23b-3p Modulating Cytoprotective Autophagy and Glutamine Addiction in Sorafenib Resistant HepG2, a,” Hepatocellular Carcinoma Cell Line 13, no. 8 (2022).

[174] H. L. Xia, Y. Lv, C. W. Xu, et al., “MiR-513c Suppresses Neuroblastoma Cell Migration, Invasion, and Proliferation Through Direct Targeting Glutaminase (GLS),” Cancer Biomarkers: Section A of Disease Markers 20, no. 4 (2017): 589-596.

[175] X. Hu, J. Miao, M. Zhang, et al., “miRNA-103a-3p Promotes Human Gastric Cancer Cell Proliferation by Targeting and Suppressing ATF7 in Vitro,” Molecules and Cells 41, no. 5 (2018): 390-400.

[176] A. Ghazaryan, J. A. Wallace, W. W. Tang, et al., “miRNA-1 Promotes Acute Myeloid Leukemia Cell Pathogenesis Through Metabolic Regulation,” Frontiers in Genetics 14 (2023): 1192799.

[177] X. Zhou, P. Wei, X. Wang, J. Zhang, and Y. Shi, “miR-141-3p Promotes the Cisplatin Sensitivity of Osteosarcoma Cell Through Targeting the Glutaminase [GLS]-Mediated Glutamine Metabolism,” Current Molecular Medicine 23, no. 2 (2023): 177-184.

[178] S. Delgir, K. Ilkhani, A. Safi, et al., “The Expression of miR-513c and miR-3163 was Downregulated in Tumor Tissues Compared With Normal Adjacent Tissue of Patients With Breast Cancer,” BMC Medical Genomics 14, no. 1 (2021): 180.

[179] M. K. Iyer, Y. S. Niknafs, R. Malik, et al., “The Landscape of Long Noncoding RNAs in the Human Transcriptome,” Nature Genetics 47, no. 3 (2015): 199-208.

[180] F. Cheng, W. Lu, C. Liu, et al., “A Genome-wide Positioning Systems Network Algorithm for in Silico Drug Repurposing,” Nature Communications 10, no. 1 (2019): 3476.

[181] H. Ling, R. Spizzo, Y. Atlasi, et al., “CCAT2, a Novel Noncoding RNA Mapping to 8q24, Underlies Metastatic Progression and Chromosomal Instability in Colon Cancer,” Genome Research 23, no. 9 (2013): 1446-1461.

[182] Y. Xin, Z. Li, H. Zheng, M. T. V. Chan, and W. Ka Kei Wu, “CCAT2: A Novel Oncogenic Long Non-Coding RNA in Human Cancers,” Cell Proliferation 50, no. 3 (2017).

[183] C. Schlicker, M. Gertz, P. Papatheodorou, B. Kachholz, C. F. Becker, and C. Steegborn, “Substrates and Regulation Mechanisms for the Human Mitochondrial Sirtuins Sirt3 and Sirt5,” Journal of Molecular Biology 382, no. 3 (2008): 790-801.

[184] M. Liao, W. Liao, N. Xu, et al., “LncRNA EPB41L4A-AS1 Regulates Glycolysis and Glutaminolysis by Mediating Nucleolar Translocation of HDAC2,” EBioMedicine 41 (2019): 200-213.

[185] W. Luan, X. Zhang, H. Ruan, J. Wang, and X. Bu, “Long Noncoding RNA OIP5-AS1 Acts as a Competing Endogenous RNA to Promote Glutamine Catabolism and Malignant Melanoma Growth by Sponging miR-217,” Journal of Cellular Physiology (2019).

[186] Q. Zhou, H. Zhan, F. Lin, et al., “LincRNA-p21 Suppresses Glutamine Catabolism and Bladder Cancer Cell Growth Through Inhibiting Glutaminase Expression,” Bioscience Reports 39, no. 4 (2019).

[187] S. J. Deng, H. Y. Chen, Z. Zeng, et al., “Nutrient Stress-Dysregulated Antisense lncRNA GLS-AS Impairs GLS-Mediated Metabolism and Represses Pancreatic Cancer Progression,” Cancer Research 79, no. 7 (2019): 1398-1412.

[188] Y. Ge, X. Yan, Y. Jin, et al., “MiRNA-192 [corrected] and miRNA-204 Directly Suppress lncRNA HOTTIP and Interrupt GLS1-Mediated Glutaminolysis in Hepatocellular Carcinoma,” PLoS Genetics 11, no. 12 (2015): e1005726.

[189] H. J. Li, X. Li, H. Pang, J. J. Pan, X. J. Xie, and W. Chen, “Long Non-coding RNA UCA1 Promotes Glutamine Metabolism by Targeting miR-16 in human Bladder Cancer,” Japanese Journal of Clinical Oncology 45, no. 11 (2015): 1055-1063.

[190] L. Liu, S. Cui, T. Wan, et al., “Long Non-coding RNA HOTAIR Acts as a Competing Endogenous RNA to Promote Glioma Progression by Sponging miR-126-5p,” Journal of Cellular Physiology 233, no. 9 (2018): 6822-6831.

[191] R. S. Redis, L. E. Vela, W. Lu, et al., “Allele-Specific Reprogramming of Cancer Metabolism by the Long Non-coding RNA CCAT2,” Molecular Cell 61, no. 4 (2016): 520-534.

[192] S. Xiang, H. Gu, L. Jin, R. F. Thorne, X. D. Zhang, and M. Wu, “LncRNA IDH1-AS1 Links the Functions of c-Myc and HIF1α via IDH1 to Regulate the Warburg Effect,” Proceedings of the National Academy of Sciences of the United States of America 115, no. 7 (2018): E1465-e1474.

[193] Y. Pan, K. D. Mansfield, C. C. Bertozzi, et al., “Multiple Factors Affecting Cellular Redox Status and Energy Metabolism Modulate Hypoxia-inducible Factor Prolyl Hydroxylase Activity in Vivo and in Vitro,” Molecular and Cellular Biology 27, no. 3 (2007): 912-925.

[194] B. Zeng, H. Ye, J. Chen, et al., “LncRNA TUG1 Sponges miR-145 to Promote Cancer Progression and Regulate Glutamine Metabolism via Sirt3/GDH Axis,” Oncotarget 8, no. 69 (2017): 113650-113661.

[195] D. B. Lombard, F. W. Alt, H. L. Cheng, et al., “Mammalian Sir2 Homolog SIRT3 Regulates Global Mitochondrial Lysine Acetylation,” Molecular and Cellular Biology 27, no. 24 (2007): 8807-8814.

[196] C. V. Dang, A. Le, and P Gao, “MYC-Induced Cancer Cell Energy Metabolism and Therapeutic Opportunities,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 15, no. 21 (2009): 6479-6483.

[197] V. Infantino, A. Santarsiero, P. Convertini, S. Todisco, and V. Iacobazzi, “Cancer Cell Metabolism in Hypoxia: Role of HIF-1 as Key Regulator and Therapeutic Target,” International Journal of Molecular Sciences 22, no. 11 (2021).

[198] P. Jaakkola, D. R. Mole, Y. M. Tian, et al., “Targeting of HIF-alpha to the von Hippel-Lindau Ubiquitylation Complex by O2-regulated Prolyl Hydroxylation,” Science 292, no. 5516 (2001): 468-472.

[199] X. Wang, Z. Gao, J. Liao, et al., “lncRNA UCA1 Inhibits Esophageal Squamous-cell Carcinoma Growth by Regulating the Wnt Signaling Pathway,” Journal of Toxicology and Environmental Health Part A 79, no. 9-10 (2016): 407-418.

[200] Q. An, C. Han, Y. Zhou, et al., “Matrine Induces Cell Cycle Arrest and Apoptosis with Recovery of the Expression of miR-126 in the A549 Non-small Cell Lung Cancer Cell Line,” Molecular Medicine Reports 14, no. 5 (2016): 4042-4048.

[201] J. Wang, Y. Zhou, X. Fei, X. Chen, and Z. Zhu, “Regulator of G-protein Signaling 3 Targeted by miR-126 Correlates With Poor Prognosis in Gastric Cancer Patients,” Anti-cancer Drugs 28, no. 2 (2017): 161-169.

[202] P. Zhang, Z. Chao, R. Zhang, et al., “Circular RNA Regulation of Myogenesis,” Cells 8, no. 8 (2019).

[203] W. R. Jeck and N. E. Sharpless, “Detecting and Characterizing Circular RNAs,” Nature Biotechnology 32, no. 5 (2014): 453-461.

[204] M. Y. Zhou, J. M. Yang, and X. D. Xiong, “The Emerging Landscape of Circular RNA in Cardiovascular Diseases,” Journal of Molecular and Cellular Cardiology 122 (2018): 134-139.

[205] D. Yang, L. Sun, Z. Li, and P. Gao, “Noncoding RNAs in Regulation of Cancer Metabolic Reprogramming,” Advances in Experimental Medicine and Biology 927 (2016): 191-215.

[206] Q. Shang, Z. Yang, R. Jia, and S. Ge, “The Novel Roles of circRNAs in Human Cancer,” Molecular Cancer 18, no. 1 (2019): 6.

[207] J. Q. Sheng, L. Liu, M. R. Wang, and P. Y. Li, “Circular RNAs in Digestive System Cancer: Potential Biomarkers and Therapeutic Targets,” American Journal of Cancer Research 8, no. 7 (2018): 1142-1156.

[208] D. Qu, B. Yan, R. Xin, and T. Ma, “A Novel Circular RNA hsa_circ_0020123 Exerts Oncogenic Properties Through Suppression of miR-144 in Non-small Cell Lung Cancer,” American Journal of Cancer Research 8, no. 8 (2018): 1387-1402.

[209] H. F. Liang, X. Z. Zhang, B. G. Liu, G. T. Jia, and W. L. Li, “Circular RNA Circ-ABCB10 Promotes Breast Cancer Proliferation and Progression Through Sponging miR-1271,” American Journal of Cancer Research 7, no. 7 (2017): 1566-1576.

[210] Y. Jiang, Y. Zhang, F. Chu, L. Xu, and H. Wu, “Circ_0032821 acts as an Oncogene in Cell Proliferation, Metastasis and Autophagy in human Gastric Cancer Cells in Vitro and in Vivo Through Activating MEK1/ERK1/2 Signaling Pathway,” Cancer Cell International 20 (2020): 74.

[211] R. Steponaitiene, J. Kupcinskas, C. Langner, et al., “Epigenetic Silencing of miR-137 is a Frequent Event in Gastric Carcinogenesis,” Molecular Carcinogenesis 55, no. 4 (2016): 376-386.

[212] Y. Du, Y. Chen, F. Wang, and L. Gu, “miR-137 Plays Tumor Suppressor Roles in Gastric Cancer Cell Lines by Targeting KLF12 and MYO1C,” Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine 37, no. 10 (2016): 13557-13569.

[213] Y. Lu, L. Li, L. Li, G. Wu, and G. Liu, “Circular RNA circHECTD1 Prevents Diosbulbin-B-sensitivity via miR-137/PBX3 Axis in Gastric Cancer,” Cancer Cell International 21, no. 1 (2021): 264.

[214] Q. Tan, C. Liu, Y. Shen, and T. Huang, “Circular RNA circ_0000517 Facilitates the Growth and Metastasis of Non-Small Cell Lung Cancer by Sponging miR-326/miR-330-5p,” Cell Journal 23, no. 5 (2021): 552-561.

[215] Q. Li, W. Wang, M. Zhang, W. Sun, W. Shi, and F. Li, “Circular RNA Circ-0016068 Promotes the Growth, Migration, and Invasion of Prostate Cancer Cells by Regulating the miR-330-3p/BMI-1 Axis as a Competing Endogenous RNA,” Frontiers in Cell and Developmental Biology 8 (2020): 827.

[216] C. Qian, S. Chen, S. Li, Y. Wang, and J. Yao, “Circ_0000003 Regulates Glutamine Metabolism and Tumor Progression of Tongue Squamous Cell Carcinoma via the miR‑330‑3p/GLS Axis,” Oncology Reports 45, no. 4 (2021).

[217] R. R. Wu, Q. Zhong, H. F. Liu, and S. B. Liu, “Role of miR-579-3p in the Development of Squamous Cell Lung Carcinoma and the Regulatory Mechanisms,” European Review for Medical and Pharmacological Sciences 23, no. 21 (2019): 9464-9470.

[218] C. J. Qian, Y. Y. Tong, Y. C. Wang, X. S. Teng, and J. Yao, “Circ_0001093 Promotes Glutamine Metabolism and Cancer Progression of Esophageal Squamous Cell Carcinoma by Targeting miR-579-3p/Glutaminase Axis,” Journal of Bioenergetics and Biomembranes 54, no. 2 (2022): 119-134.

[219] Z. Liang, B. Zhao, J. Hou, J. Zheng, and G. Xin, “CircRNA Circ-OGDH (hsa_circ_0003340) Acts as a ceRNA to Regulate Glutamine Metabolism and Esophageal Squamous Cell Carcinoma Progression by the miR-615-5p/PDX1 Axis,” Cancer Management and Research 13 (2021): 3041-3053.

[220] T. Zhu, Y. Cen, Z. Chen, et al., “Oncogenic circTICRR Suppresses Autophagy via Binding to HuR Protein and Stabilizing GLUD1 mRNA in Cervical Cancer,” Cell Death & Disease 13, no. 5 (2022): 479.

[221] Y. Zhou, Y. Zhan, W. Jiang, H. Liu, and S. Wei, “Long Noncoding RNAs and Circular RNAs in the Metabolic Reprogramming of Lung Cancer: Functions, Mechanisms, and Clinical Potential,” Oxidative Medicine and Cellular Longevity 2022 (2022): 4802338.

[222] H. Fu, J. Hardy, and K. E. Duff, “Selective Vulnerability in Neurodegenerative Diseases,” Nature Neuroscience 21, no. 10 (2018): 1350-1358.

[223] L. Gan, M. R. Cookson, L. Petrucelli, and A. R. La Spada, “Converging Pathways in Neurodegeneration, From Genetics to Mechanisms,” Nature Neuroscience 21, no. 10 (2018): 1300-1309.

[224] E. K. Pissadaki and J. P. Bolam, “The Energy Cost of Action Potential Propagation in Dopamine Neurons: Clues to Susceptibility in Parkinson's disease,” Frontiers in Computational Neuroscience 7 (2013).

[225] C. Pacelli, N. Giguère, M. J. Bourque, M. Lévesque, R. S. Slack, and L. Trudeau, “Elevated Mitochondrial Bioenergetics and Axonal Arborization Size Are Key Contributors to the Vulnerability of Dopamine Neurons,” Current Biology: CB 25, no. 18 (2015): 2349-2360.

[226] R. Bornstein, M. T. Mulholland, M. Sedensky, P. Morgan, and S. C. Johnson, “Glutamine Metabolism in Diseases Associated With Mitochondrial Dysfunction,” Molecular and Cellular Neurosciences 126 (2023): 103887.

[227] R. Han, J. Liang, and B. Zhou, “Glucose Metabolic Dysfunction in Neurodegenerative Diseases-New Mechanistic Insights and the Potential of Hypoxia as a Prospective Therapy Targeting Metabolic Reprogramming,” International Journal of Molecular Sciences 22, no. 11 (2021).

[228] S. C. Johnson, B. Gonzalez, Q. Zhang, B. Milholland, Z. Zhang, and Y. Suh, “Network Analysis of Mitonuclear GWAS Reveals Functional Networks and Tissue Expression Profiles of Disease-associated Genes,” Human Genetics 136, no. 1 (2017): 55-65.

[229] K. B. Magalingam, A. Radhakrishnan, N. S. Ping, and N. Haleagrahara, “Current Concepts of Neurodegenerative Mechanisms in Alzheimer's Disease,” BioMed Research International 2018 (2018): 3740461.

[230] R. D. Terry and P. Davies, “Dementia of the Alzheimer Type,” Annual Review of Neuroscience 3 (1980): 77-95.

[231] L. Wu, P. Rosa-Neto, G. Y. Hsiung, et al., “Early-onset Familial Alzheimer's Disease (EOFAD),” The Canadian Journal of Neurological Sciences Le Journal Canadien Des Sciences Neurologiques 39, no. 4 (2012): 436-445.

[232] S. L. Kirvell, M. Esiri, and P. T. Francis, “Down-regulation of Vesicular Glutamate Transporters Precedes Cell Loss and Pathology in Alzheimer's Disease,” Journal of Neurochemistry 98, no. 3 (2006): 939-950.

[233] J. W. Griffin and P. C. Bradshaw, “Amino Acid Catabolism in Alzheimer's Disease Brain: Friend or Foe?,” Oxidative Medicine and Cellular Longevity 2017 (2017): 5472792.

[234] R. Wang and P. H. Reddy, “Role of Glutamate and NMDA Receptors in Alzheimer's Disease,” Journal of Alzheimer's Disease: JAD 57, no. 4 (2017): 1041-1048.

[235] J. Liu, L. Chang, Y. Song, H. Li, and Y. Wu, “The Role of NMDA Receptors in Alzheimer's Disease,” Frontiers in Neuroscience 13 (2019): 43.

[236] S. Huang, H. Tong, M. Lei, et al., “Astrocytic Glutamatergic Transporters are Involved in Aβ-Induced Synaptic Dysfunction,” Brain Research 1678 (2018): 129-137.

[237] S. Matsunaga, T. Kishi, I. Nomura, et al., “The Efficacy and Safety of Memantine for the Treatment of Alzheimer's Disease,” Expert Opinion on Drug Safety 17, no. 10 (2018): 1053-1061.

[238] D. D. Li, Y. H. Zhang, W. Zhang, and P. Zhao, “Meta-Analysis of Randomized Controlled Trials on the Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the Treatment of Alzheimer's Disease,” Frontiers in Neuroscience 13 (2019): 472.

[239] Z. Zhang, S. Zhang, P. Fu, et al., “Roles of Glutamate Receptors in Parkinson's Disease,” International Journal of Molecular Sciences 20, no. 18 (2019).

[240] J. Jankovic, “Parkinson's Disease: Clinical Features and Diagnosis,” Neurosurgery, and Psychiatry 79, no. 4 (2008): 368-376.

[241] A. Spivey, “Rotenone and Paraquat Linked to Parkinson's Disease: Human Exposure Study Supports Years of Animal Studies,” Environmental Health Perspectives 119, no. 6 (2011): A259.

[242] G. Egger, G. Liang, A. Aparicio, and P. A. Jones, “Epigenetics in human Disease and Prospects for Epigenetic Therapy,” Nature 429, no. 6990 (2004): 457-463.

[243] J. Lotharius and P. Brundin, “Pathogenesis of Parkinson's Disease: Dopamine, Vesicles and Alpha-synuclein,” Nature Reviews Neuroscience 3, no. 12 (2002): 932-942.

[244] B. Dehay, J. Bové, N. Rodríguez-Muela, et al., “Pathogenic Lysosomal Depletion in Parkinson's Disease,” The Journal of Neuroscience: the Official Journal of the Society for Neuroscience 30, no. 37 (2010): 12535-12544.

[245] G. DeMaagd and A. Philip, “Parkinson's Disease and Its Management: Part 1: Disease Entity, Risk Factors, Pathophysiology, Clinical Presentation, and Diagnosis,” P & T: a peer-reviewed Journal for Formulary Management 40, no. 8 (2015): 504-532.

[246] B. Vanle, W. Olcott, J. Jimenez, L. Bashmi, I. Danovitch, and W. W. IsHak, “NMDA Antagonists for Treating the Non-Motor Symptoms in Parkinson's Disease,” Translational Psychiatry 8, no. 1 (2018): 117.

[247] W. Robberecht and T. Philips, “The Changing Scene of Amyotrophic Lateral Sclerosis,” Nature Reviews Neuroscience 14, no. 4 (2013): 248-264.

[248] A. Kumar, D. Ghosh, and R. L. Singh, “Amyotrophic Lateral Sclerosis and Metabolomics: Clinical Implication and Therapeutic Approach,” Journal of Biomarkers (2013): 538765.

[249] D. Bäumer, K. Talbot, and M. R. Turner, “Advances in Motor Neurone Disease,” Journal of the Royal Society of Medicine 107, no. 1 (2014): 14-21.

[250] M. L. Fiszman, K. C. Ricart, A. Latini, G. Rodríguez, and R. E. Sica, “In Vitro Neurotoxic Properties and Excitatory Aminoacids Concentration in the Cerebrospinal Fluid of amyotrophic Lateral sclerosis Patients. Relationship With the Degree of Certainty of Disease Diagnoses,” Acta Neurologica Scandinavica 121, no. 2 (2010): 120-126.

[251] O. Spreux-Varoquaux, G. Bensimon, L. Lacomblez, et al., “Glutamate Levels in Cerebrospinal Fluid in Amyotrophic Lateral sclerosis: A Reappraisal Using a New HPLC Method With Coulometric Detection in a Large Cohort of Patients,” Journal of the Neurological Sciences 193, no. 2 (2002): 73-78.

[252] L. T. Rosenblum and D. Trotti, “EAAT2 and the Molecular Signature of Amyotrophic Lateral Sclerosis,” Advances in Neurobiology 16 (2017): 117-136.

[253] W. van Rheenen, R. A. A. van der Spek, M. K. Bakker, et al., “Common and Rare Variant Association Analyses in amyotrophic Lateral sclerosis Identify 15 Risk Loci With Distinct Genetic Architectures and Neuron-specific Biology,” Nature Genetics 53, no. 12 (2021): 1636-1648.

[254] M. C. Hogg, L. Halang, I. Woods, K. S. Coughlan, and J. H. M. Prehn, “Riluzole Does Not Improve Lifespan or Motor Function in Three ALS Mouse Models,” Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration 19, no. 5-6 (2018): 438-445.

[255] G. M. Chowdhury, M. Banasr, R. A. de Graaf, D. L. Rothman, K. L. Behar, and G. Sanacora, “Chronic Riluzole Treatment Increases Glucose Metabolism in Rat Prefrontal Cortex and Hippocampus,” Journal of Cerebral Blood Flow and Metabolism: Official Journal of the International Society of Cerebral Blood Flow and Metabolism 28, no. 12 (It was foretold the princess would bear an illustrious son): 1892-1897.

[256] M. C. Bellingham, “Pre- and Postsynaptic Mechanisms Underlying Inhibition of Hypoglossal Motor Neuron Excitability by Riluzole,” Journal of Neurophysiology 110, no. 5 (2013): 1047-1061.

[257] R. Cai, Y. Zhang, J. E. Simmering, et al., “Enhancing Glycolysis Attenuates Parkinson's disease Progression in Models and Clinical Databases,” The Journal of Clinical Investigation 129, no. 10 (2019): 4539-4549.

[258] A. Hanaford and S. C. Johnson, “The Immune System as a Driver of Mitochondrial Disease Pathogenesis: A Review of Evidence,” Orphanet Journal of Rare Diseases 17, no. 1 (2022): 335.

[259] N. Cawley, A. Molloy, L. Cassidy, and N. Tubridy, “Late-onset Progressive Visual Loss in a Man With Unusual MRI Findings: MS, Harding's, Leber's or Leber's Plus?,” Irish Journal of Medical Science 179, no. 4 (2010): 599-601.

[260] D. Bargiela and P. F. Chinnery, “Mitochondria in Neuroinflammation—Multiple Sclerosis (MS), Leber Hereditary Optic Neuropathy (LHON) and LHON-MS,” Neuroscience Letters 710 (2019): 132932.

[261] H. Polacek, E. Kantorova, P. Hnilicova, M. Grendar, K. Zelenak, and E Kurca, “Increased Glutamate and Deep Brain Atrophy Can Predict the Severity of Multiple Sclerosis,” Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia 163, no. 1 (2019): 45-53.

[262] F. Yang, S. C. Wu, Z. X. Ling, et al., “Altered Plasma Metabolic Profiles in Chinese Patients with Multiple Sclerosis,” Frontiers in Immunology 12 (2021): 792711.

[263] K. M. Swanberg, A. V. Kurada, H. Prinsen, and C. Juchem, “Multiple Sclerosis Diagnosis and Phenotype Identification by Multivariate Classification of in Vivo Frontal Cortex Metabolite Profiles,” Scientific Reports 12, no. 1 (2022): 13888.

[264] K. R. Hollinger, M. D. Smith, L. A. Kirby, et al., “Glutamine Antagonism Attenuates Physical and Cognitive Deficits in a Model of MS,” Neurology(R) Neuroimmunology & Neuroinflammation 6, no. 6 (2019).

[265] A. B. Ettinger, M. L. Reed, J. F. Goldberg, and R. M. Hirschfeld, “Prevalence of Bipolar Symptoms in Epilepsy vs Other Chronic Health Disorders,” Neurology 65, no. 4 (2005): 535-540.

[266] Y. Kim, R. Santos, F. H. Gage, and M. C. Marchetto, “Molecular Mechanisms of Bipolar Disorder: Progress Made and Future Challenges,” Frontiers in Cellular Neuroscience 11 (2017): 30.

[267] A. M. Cataldo, D. L. McPhie, N. T. Lange, et al., “Abnormalities in Mitochondrial Structure in Cells From Patients With Bipolar Disorder,” The American Journal of Pathology 177, no. 2 (2010): 575-585.

[268] J. Mertens, Q. W. Wang, Y. Kim, et al., “Differential Responses to Lithium in Hyperexcitable Neurons From Patients With Bipolar Disorder,” Nature 527, no. 7576 (2015): 95-99.

[269] N. Fayed, E. Andrés, L. Viguera, P. J. Modrego, and J. Garcia-Campayo, “Higher Glutamate+Glutamine and Reduction of N-acetylaspartate in Posterior Cingulate According to Age Range in Patients With Cognitive Impairment and/or Pain,” Academic Radiology 21, no. 9 (2014): 1211-1217.

[270] B. Amann and H. Grunze, “Neurochemical Underpinnings in Bipolar Disorder and Epilepsy,” Epilepsia, no. 46 Suppl 4 (2005): 26-30.

[271] C. G. Wasterlain, K. W. Thompson, L. Suchomelova, and J. Niquet, “Brain Energy Metabolism During Experimental Neonatal Seizures,” Neurochemical Research 35, no. 12 (2010): 2193-2198.

[272] N. G. Norwitz, S. Sethi, and C. M. Palmer, “Ketogenic Diet as a Metabolic Treatment for Mental Illness,” Current Opinion in Endocrinology, Diabetes, and Obesity 27, no. 5 (2020): 269-274.

[273] I. D'Andrea Meira, T. T. Romão, H. J. do Pires Prado, L. T. Krüger, M. E. P. Pires, and P. O. da Conceição, “Ketogenic Diet and Epilepsy: What We Know So Far,” Frontiers in Neuroscience 13 (2019): 5.

[274] C. Stathopoulou, D. Nikoleri, and G. Bertsias, “Immunometabolism: An Overview and Therapeutic Prospects in Autoimmune Diseases,” Immunotherapy 11, no. 9 (2019): 813-829.

[275] X. Teng, J. Brown, S. C. Choi, W. Li, and L. Morel, “Metabolic Determinants of Lupus Pathogenesis,” Immunological Reviews 295, no. 1 (2020): 167-186.

[276] X. Zhang, G. Wang, Y. Bi, Z. Jiang, and X. Wang, “Inhibition of Glutaminolysis Ameliorates Lupus by Regulating T and B Cell Subsets and Downregulating the mTOR/P70S6K/4EBP1 and NLRP3/Caspase-1/IL-1β Pathways in MRL/Lpr Mice,” International Immunopharmacology 112 (2022): 109133.

[277] A. K. Jha, S. C. Huang, A. Sergushichev, et al., “Network Integration of Parallel Metabolic and Transcriptional Data Reveals Metabolic Modules That Regulate Macrophage Polarization,” Immunity 42, no. 3 (2015): 419-430.

[278] J. Crawford and H. J. Cohen, “The Essential Role of L-glutamine in Lymphocyte Differentiation in Vitro,” Journal of Cellular Physiology 124, no. 2 (1985): 275-282.

[279] Y. Yin, S. C. Choi, Z. Xu, et al., “Normalization of CD4+ T Cell Metabolism Reverses Lupus,” Science Translational Medicine 7, no. 274 (2015): 274ra218.

[280] K. A. Frauwirth, J. L. Riley, M. H. Harris, et al., “The CD28 Signaling Pathway Regulates Glucose Metabolism,” Immunity 16, no. 6 (2002): 769-777.

[281] S. Weidinger, L. A. Beck, T. Bieber, K. Kabashima, and A. D. Irvine, “Atopic Dermatitis,” Nature Reviews Disease Primers 4, no. 1 (2018).

[282] G. Nygaard and G. S. Firestein, “Restoring Synovial Homeostasis in Rheumatoid Arthritis by Targeting Fibroblast-Like Synoviocytes,” Nature Reviews Rheumatology 16, no. 6 (2020): 316-333.

[283] D. E. Mahmoud, W. Kaabachi, N. Sassi, et al., “The Synovial Fluid Fibroblast-Like Synoviocyte: A Long-neglected Piece in the Puzzle of Rheumatoid Arthritis Pathogenesis,” Frontiers in Immunology 13 (2022): 942417.

[284] M. Masoumi, M. Mehrabzadeh, S. Mahmoudzehi, et al., “Role of Glucose Metabolism in Aggressive Phenotype of Fibroblast-Like Synoviocytes: Latest Evidence and Therapeutic Approaches in Rheumatoid Arthritis,” International Immunopharmacology 89, no. Pt A (2020): 107064.

[285] S. Kim, J. Hwang, J. Xuan, Y. H. Jung, H. S. Cha, and K. H. Kim, “Global Metabolite Profiling of Synovial Fluid for the Specific Diagnosis of Rheumatoid Arthritis From Other Inflammatory Arthritis,” PLoS ONE 9, no. 6 (2014): e97501.

[286] S. Takahashi, J. Saegusa, S. Sendo, et al., “Glutaminase 1 Plays a Key Role in the Cell Growth of Fibroblast-Like Synoviocytes in Rheumatoid Arthritis,” Arthritis Research & Therapy 19, no. 1 (2017): 76.

[287] B. R. Yoon, Y. J. Oh, S. W. Kang, E. B. Lee, and W. W. Lee, “Role of SLC7A5 in Metabolic Reprogramming of Human Monocyte/Macrophage Immune Responses,” Frontiers in Immunology 9 (2018): 53.

[288] T. B. Levring, A. K. Hansen, B. L. Nielsen, et al., “Activated human CD4+ T Cells Express Transporters for both Cysteine and Cystine,” Scientific Reports 2 (2012): 266.

[289] M. Nakaya, Y. Xiao, X. Zhou, et al., “Inflammatory T Cell Responses Rely on Amino Acid Transporter ASCT2 Facilitation of Glutamine Uptake and mTORC1 Kinase Activation,” Immunity 40, no. 5 (2014): 692-705.

[290] Z. Wen, K. Jin, Y. Shen, et al., “N-Myristoyltransferase Deficiency Impairs Activation of Kinase AMPK and Promotes Synovial Tissue Inflammation,” Nature Immunology 20, no. 3 (2019): 313-325.

[291] C. M. Weyand, M. Zeisbrich, and J. J. Goronzy, “Metabolic Signatures of T-cells and Macrophages in Rheumatoid Arthritis,” Current Opinion in Immunology 46 (2017): 112-120.

[292] M. Biniecka, M. Canavan, T. McGarry, et al., “Dysregulated Bioenergetics: A Key Regulator of Joint Inflammation,” Annals of the Rheumatic Diseases 75, no. 12 (2016): 2192-2200.

[293] G. Abboud, S. C. Choi, N. Kanda, L. Zeumer-Spataro, D. C. Roopenian, and L. Morel, “Inhibition of Glycolysis Reduces Disease Severity in an Autoimmune Model of Rheumatoid Arthritis,” Frontiers in Immunology 9 (2018): 1973.

[294] T. Okano, J. Saegusa, K. Nishimura, et al., “3-bromopyruvate Ameliorate Autoimmune Arthritis by Modulating Th17/Treg Cell Differentiation and Suppressing Dendritic Cell Activation,” Scientific Reports 7 (2017): 42412.

[295] R. E. Oberkersch, G. Pontarin, M. Astone, et al., “Aspartate Metabolism in Endothelial Cells Activates the mTORC1 Pathway to Initiate Translation During Angiogenesis,” Developmental Cell 57, no. 10 (2022): 1248.

[296] P. J. Basso, V. Andrade-Oliveira, and N. O. S. Câmara, “Targeting Immune Cell Metabolism in Kidney Diseases,” Nature Reviews Nephrology 17, no. 7 (2021): 465-480.

[297] Y. Cao, X. Chen, Z. Zhu, et al., “STING Contributes to Lipopolysaccharide-Induced Tubular Cell Inflammation and Pyroptosis by Activating Endoplasmic Reticulum Stress in Acute Kidney Injury,” Cell Death & Disease 15, no. 3 (2024): 217.

[298] E. M. Flowers, J. Sudderth, L. Zacharias, et al., “Lkb1 Deficiency Confers Glutamine Dependency in Polycystic Kidney Disease,” Nature Communications 9, no. 1 (2018): 814.

[299] L. Zhao, Y. Hao, S. Tang, X. Han, R. Li, and X. Zhou, “Energy Metabolic Reprogramming Regulates Programmed Cell Death of Renal Tubular Epithelial Cells and Might Serve as a New Therapeutic Target for Acute Kidney Injury,” Frontiers in Cell and Developmental Biology 11 (2023): 1276217.

[300] K. Lee, E. A. Thompson, S. Gharaie, et al., “T Cell Metabolic Reprogramming in Acute Kidney Injury and Protection by Glutamine Blockade,” JCI Insight 8, no. 12 (2023).

[301] Z. Y. Peng, F. Zhou, H. Z. Wang, et al., “The Anti-oxidant Effects are Not the Main Mechanism for Glutamine's Protective Effects on Acute Kidney Injury in Mice,” European Journal of Pharmacology 705, no. 1-3 (2013): 11-19.

[302] Y. M. Hu, M. H. Pai, C. L. Yeh, Y. C. Hou, and S. L. Yeh, “Glutamine Administration Ameliorates Sepsis-Induced Kidney Injury by Downregulating the High-Mobility Group Box Protein-1-Mediated Pathway in Mice,” American Journal of Physiology Renal Physiology 302, no. 1 (2012): F150-158.

[303] Y. S. Kim, M. H. Jung, M. Y. Choi, et al., “Glutamine Attenuates Tubular Cell Apoptosis in Acute Kidney Injury via Inhibition of the c-Jun N-terminal Kinase Phosphorylation of 14-3-3,” Critical Care Medicine 37, no. 6 (2009): 2033-2044.

[304] P. C. Grayson, S. Eddy, J. N. Taroni, et al., “Metabolic Pathways and Immunometabolism in Rare Kidney Diseases,” Annals of the Rheumatic Diseases 77, no. 8 (2018): 1226-1233.

[305] S. Y. Chan and J. Loscalzo, “Pathogenic Mechanisms of Pulmonary Arterial Hypertension,” Journal of Molecular and Cellular Cardiology 44, no. 1 (2008): 14-30.

[306] M. Rabinovitch, “Molecular Pathogenesis of Pulmonary Arterial Hypertension,” The Journal of Clinical Investigation 118, no. 7 (2008): 2372-2379.

[307] T. Bertero, W. M. Oldham, K. A. Cottrill, et al., “Vascular Stiffness Mechanoactivates YAP/TAZ-Dependent Glutaminolysis to Drive Pulmonary Hypertension,” The Journal of Clinical Investigation 126, no. 9 (2016): 3313-3335.

[308] J. Ge, H. Cui, N. Xie, et al., “Glutaminolysis Promotes Collagen Translation and Stability via α-Ketoglutarate-Mediated mTOR Activation and Proline Hydroxylation,” American Journal of Respiratory Cell and Molecular Biology 58, no. 3 (2018): 378-390.

[309] L. Piao, Y. H. Fang, K. Parikh, J. J. Ryan, P. T. Toth, and S. L. Archer, “Cardiac Glutaminolysis: A Maladaptive Cancer Metabolism Pathway in the Right Ventricle in Pulmonary Hypertension,” Journal of Molecular Medicine 91, no. 10 (2013): 1185-1197.

[310] R. M. Tuder, L. A. Davis, and B. B. Graham, “Targeting Energetic Metabolism: A New Frontier in the Pathogenesis and Treatment of Pulmonary Hypertension,” American Journal of Respiratory and Critical Care Medicine 185, no. 3 (2012): 260-266.

[311] K. R. Stenmark, E. Nozik-Grayck, E. Gerasimovskaya, et al., “The Adventitia: Essential Role in Pulmonary Vascular Remodeling,” Comprehensive Physiology 1, no. 1 (2011): 141-161.

[312] S. C. Zimmermann, B. Duvall, and T. Tsukamoto, “Recent Progress in the Discovery of Allosteric Inhibitors of Kidney-Type Glutaminase,” Journal of Medicinal Chemistry 62, no. 1 (2019): 46-59.

[313] Y. K. Choi and K. G. Park, “Targeting Glutamine Metabolism for Cancer Treatment,” Biomolecules & Therapeutics 26, no. 1 (2018): 19-28.

[314] P. A. Jänne, A. T. Shaw, J. R. Pereira, et al., “Selumetinib plus Docetaxel for KRAS-Mutant Advanced Non-Small-Cell Lung Cancer: A Randomised, Multicentre, Placebo-Controlled, Phase 2 Study,” The Lancet Oncology 14, no. 1 (2013): 38-47.

[315] J. M. Ostrem, U. Peters, M. L. Sos, J. A. Wells, and K. M. Shokat, “K-Ras(G12C) Inhibitors Allosterically Control GTP Affinity and Effector Interactions,” Nature 503, no. 7477 (2013): 548-551.

[316] P. Lito, M. Solomon, L. S. Li, R. Hansen, and N. Rosen, “Allele-Specific Inhibitors Inactivate Mutant KRAS G12C by a Trapping Mechanism,” Science 351, no. 6273 (2016): 604-608.

[317] T. Akizawa, I. C. Macdougall, J. S. Berns, et al., “Long-Term Efficacy and Safety of Molidustat for Anemia in Chronic Kidney Disease: DIALOGUE Extension Studies,” American Journal of Nephrology 49, no. 4 (2019): 271-280.

[318] H. Miao, D. Q. Li, A. Mukherjee, et al., “EphA2 mediates Ligand-dependent Inhibition and Ligand-Independent Promotion of Cell Migration and Invasion via a Reciprocal Regulatory Loop with Akt,” Cancer Cell 16, no. 1 (2009): 9-20.

[319] K. H. Paraiso, M. Das Thakur, B. Fang, et al., “Ligand-independent EPHA2 Signaling Drives the Adoption of a Targeted Therapy-mediated Metastatic Melanoma Phenotype,” Cancer Discovery 5, no. 3 (2015): 264-273.

[320] H. Miao, N. W. Gale, H. Guo, et al., “EphA2 promotes Infiltrative Invasion of Glioma Stem Cells in Vivo Through Cross-Talk with Akt and Regulates Stem Cell Properties,” Oncogene 34, no. 5 (2015): 558-567.

[321] L. M. Mustachio, A. Chelariu-Raicu, L. Szekvolgyi, and J. Roszik, “Targeting KRAS in Cancer: Promising Therapeutic Strategies,” Cancers 13, no. 6 (2021).

[322] M. Piffoux, E. Eriau, and P. A. Cassier, “Autophagy as a Therapeutic Target in Pancreatic Cancer,” British Journal of Cancer 124, no. 2 (2021): 333-344.

[323] N. J. Mabjeesh, D. Escuin, T. M. LaVallee, et al., “2ME2 Inhibits Tumor Growth and Angiogenesis by Disrupting Microtubules and Dysregulating HIF,” Cancer Cell 3, no. 4 (2003): 363-375.

[324] X. Liu, S. Chen, J. Tu, W. Cai, and Q. Xu, “HSP90 inhibits Apoptosis and Promotes Growth by Regulating HIF-1α Abundance in Hepatocellular Carcinoma,” International Journal of Molecular Medicine 37, no. 3 (2016): 825-835.

[325] D. M. Hutt, D. M. Roth, H. Vignaud, C. Cullin, and M. Bouchecareilh, “The Histone Deacetylase Inhibitor, Vorinostat, Represses Hypoxia Inducible Factor 1 Alpha Expression Through Translational Inhibition,” PLoS ONE 9, no. 8 (2014): e106224.

[326] L. M. Greenberger, I. D. Horak, D. Filpula, et al., “A RNA Antagonist of Hypoxia-Inducible Factor-1alpha, EZN-2968, Inhibits Tumor Cell Growth,” Molecular Cancer Therapeutics 7, no. 11 (2008): 3598-3608.

[327] P. Sapra, P. Kraft, F. Pastorino, et al., “Potent and Sustained Inhibition of HIF-1α and Downstream Genes by a Polyethyleneglycol-SN38 Conjugate, EZN-2208, Results in Anti-Angiogenic Effects,” Angiogenesis 14, no. 3 (2011): 245-253.

[328] S. Mohsen, P. T. Sobash, G. F. Algwaiz, N. Nasef, S. A. Al-Zeidaneen, and N. A. Karim, “Autophagy Agents in Clinical Trials for Cancer Therapy: A Brief Review,” Current Oncology 29, no. 3 (2022): 1695-1708.

[329] M. A. Sekeres, J. Watts, A. Radinoff, et al., “Randomized Phase 2 Trial of Pevonedistat plus Azacitidine versus Azacitidine for Higher-risk MDS/CMML or Low-Blast AML,” Leukemia 35, no. 7 (2021): 2119-2124.

[330] R. K. Amaravadi and J. D. Winkler, “Lys05: A New Lysosomal Autophagy Inhibitor,” Autophagy 8, no. 9 (2012): 1383-1384.

[331] Q. McAfee, Z. Zhang, A. Samanta, et al., “Autophagy Inhibitor Lys05 Has Single-Agent Antitumor Activity and Reproduces the Phenotype of a Genetic Autophagy Deficiency,” Proceedings of the National Academy of Sciences of the United States of America 109, no. 21 (2012): 8253-8258.

[332] J. S. Carew, C. M. Espitia, W. Zhao, et al., “Disruption of Autophagic Degradation With ROC-325 Antagonizes Renal Cell Carcinoma Pathogenesis,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 23, no. 11 (2017): 2869-2879.

[333] S. Brun, F. Bassissi, C. Serdjebi, et al., “GNS561, a New Lysosomotropic Small Molecule, for the Treatment of Intrahepatic Cholangiocarcinoma,” Investigational New Drugs 37, no. 6 (2019): 1135-1145.

[334] C. Commisso, S. M. Davidson, R. G. Soydaner-Azeloglu, et al., “Macropinocytosis of Protein is an Amino Acid Supply Route in Ras-Transformed Cells,” Nature 497, no. 7451 (2013): 633-637.

[335] G. L. Bumgardner, P. G. Stock, W. D. Payne, J. S. Najarian, and N. L. Ascher, “Comparison of the Results of Liver Transplantation in Children and Adults],” Der Chirurg; Zeitschrift Fur Alle Gebiete Der Operativen Medizen 59, no. 8 (1988): 526-535.

[336] P. J. Goodwin, B. E. Chen, K. A. Gelmon, et al., “Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients with Breast Cancer: The MA.32 Randomized Clinical Trial,” Jama 327, no. 20 (2022): 1963-1973.

[337] K. M. Dalton, T. L. Lochmann, K. V. Floros, et al., “Catastrophic ATP Loss Underlies a Metabolic Combination Therapy Tailored for MYCN-amplified Neuroblastoma,” Proceedings of the National Academy of Sciences of the United States of America 118, no. 13 (2021).

[338] S. E. Conneely and A. M. Stevens, “Acute Myeloid Leukemia in Children: Emerging Paradigms in Genetics and New Approaches to Therapy,” Current Oncology Reports 23, no. 2 (2021): 16.

[339] H. Takahashi, R. C. Koehler, S. W. Brusilow, and R. J. Traystman, “Inhibition of Brain Glutamine Accumulation Prevents Cerebral Edema in Hyperammonemic Rats,” The American Journal of Physiology 261 (1991): H825-829. Pt 2.

[340] T. Jonung, P. Rigotti, B. Jeppsson, J. H. James, J. C. Peters, and J. E. Fischer, “Methionine Sulfoximine Prevents the Accumulation of Large Neutral Amino Acids in Brain of Hyperammonemic Rats,” The Journal of Surgical Research 36, no. 4 (1984): 349-353.

[341] M. J. Lukey, K. F. Wilson, and R. A. Cerione, “Therapeutic Strategies Impacting Cancer Cell Glutamine Metabolism,” Future Medicinal Chemistry 5, no. 14 (2013): 1685-1700.

[342] V. I. Avramis and E. H. Panosyan, “Pharmacokinetic/Pharmacodynamic Relationships of Asparaginase Formulations: The Past, the Present and Recommendations for the Future,” Clinical Pharmacokinetics 44, no. 4 (2005): 367-393.

[343] P. Newsholme, R. Curi, T. C. Pithon Curi, C. J. Murphy, C. Garcia, and M. Pires de Melo, “Glutamine Metabolism by Lymphocytes, Macrophages, and Neutrophils: Its Importance in Health and Disease,” The Journal of Nutritional Biochemistry 10, no. 6 (1999): 316-324.

[344] M. I. Gross, S. D. Demo, J. B. Dennison, et al., “Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-negative Breast Cancer,” Molecular Cancer Therapeutics 13, no. 4 (2014): 890-901.

[345] M. Endicott, M. Jones, and J. Hull, “Amino Acid Metabolism as a Therapeutic Target in Cancer: A Review,” Amino Acids 53, no. 8 (2021): 1169-1179.

[346] Q. Zhou, W. Lin, C. Wang, et al., “Neddylation Inhibition Induces Glutamine Uptake and Metabolism by Targeting CRL3(SPOP) E3 Ligase in Cancer Cells,” Nature Communications 13, no. 1 (2022): 3034.

[347] H. C. Yoo, Y. C. Yu, Y. Sung, and J. M. Han, “Glutamine Reliance in Cell Metabolism,” Experimental & Molecular Medicine 52, no. 9 (2020): 1496-1516.

[348] M. Hassanein, J. Qian, M. D. Hoeksema, et al., “Targeting SLC1a5-mediated Glutamine Dependence in Non-Small Cell Lung Cancer,” International Journal of Cancer 137, no. 7 (2015): 1587-1597.

[349] M. L. Schulte, A. Fu, P. Zhao, et al., “Pharmacological Blockade of ASCT2-Dependent Glutamine Transport Leads to Antitumor Efficacy in Preclinical Models,” Nature Medicine 24, no. 2 (2018): 194-202.

[350] L. Koch, “Functional Genomics: Screening for lncRNA Function,” Nature Reviews Genetics 18, no. 2 (2017): 70.

[351] L. A. Gilbert, M. A. Horlbeck, B. Adamson, et al., “Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation,” Cell 159, no. 3 (2014): 647-661.

[352] P. I. Thakore, A. M. D'Ippolito, L. Song, et al., “Highly Specific Epigenome Editing by CRISPR-Cas9 Repressors for Silencing of Distal Regulatory Elements,” Nature Methods 12, no. 12 (2015): 1143-1149.

[353] Z. E. Stine, Z. T. Schug, J. M. Salvino, and C. V. Dang, “Targeting Cancer Metabolism in the Era of Precision Oncology,” Nature Reviews Drug Discovery 21, no. 2 (2022): 141-162.

[354] M. Nakagawa, F. Nakatani, H. Matsunaga, et al., “Selective Inhibition of Mutant IDH1 by DS-1001b Ameliorates Aberrant Histone Modifications and Impairs Tumor Activity in Chondrosarcoma,” Oncogene 38, no. 42 (2019): 6835-6849.

[355] J. A. Caravella, J. Lin, R. B. Diebold, et al., “Structure-Based Design and Identification of FT-2102 (Olutasidenib), a Potent Mutant-Selective IDH1 Inhibitor,” Journal of Medicinal Chemistry 63, no. 4 (2020): 1612-1623.

[356] K. M. Lemberg, S. S. Gori, T. Tsukamoto, R. Rais, and B. S. Slusher, “Clinical Development of Metabolic Inhibitors for Oncology,” The Journal of Clinical Investigation 132, no. 1 (2022).

[357] J. B. Wang, J. W. Erickson, R. Fuji, et al., “Targeting Mitochondrial Glutaminase Activity Inhibits Oncogenic Transformation,” Cancer Cell 18, no. 3 (2010): 207-219.

[358] M. M. Robinson, S. J. McBryant, T. Tsukamoto, et al., “Novel Mechanism of Inhibition of Rat Kidney-Type Glutaminase by Bis-2-(5-Phenylacetamido-1,2,4-Thiadiazol-2-yl)ethyl Sulfide (BPTES),” The Biochemical Journal 406, no. 3 (2007): 407-414.

[359] R. C. Willis and J. E. Seegmiller, “The Inhibition by 6-Diazo-5-oxo-l-Norleucine of Glutamine Catabolism of the Cultured human Lymphoblast,” Journal of Cellular Physiology 93, no. 3 (1977): 375-382.

[360] S. C. Zimmermann, E. F. Wolf, A. Luu, et al., “Allosteric Glutaminase Inhibitors Based on a 1,4-Di(5-amino-1,3,4-thiadiazol-2-yl)Butane Scaffold,” ACS Medicinal Chemistry Letters 7, no. 5 (2016): 520-524.

[361] B. J. Altman, Z. E. Stine, and C. V. Dang, “From Krebs to Clinic: Glutamine Metabolism to Cancer Therapy,” Nature Reviews Cancer 16, no. 11 (2016): 749.

[362] K. Wahi and J. Holst, “ASCT2: A Potential Cancer Drug Target,” Expert Opinion on Therapeutic Targets 23, no. 7 (2019): 555-558.

[363] K. Thangavelu, Q. Y. Chong, B. C. Low, and J. Sivaraman, “Structural Basis for the Active Site Inhibition Mechanism of Human Kidney-Type Glutaminase (KGA),” Scientific Reports 4 (2014): 3827.

[364] G. S. Ahluwalia, J. L. Grem, Z. Hao, and D. A. Cooney, “Metabolism and Action of Amino Acid Analog Anti-Cancer Agents,” Pharmacology & Therapeutics 46, no. 2 (1990): 243-271.

[365] C. Li, A. Allen, J. Kwagh, et al., “Green Tea Polyphenols Modulate Insulin Secretion by Inhibiting Glutamate Dehydrogenase,” The Journal of Biological Chemistry 281, no. 15 (2006): 10214-10221.

[366] E. Le Deunff, P. Beauclair, C. Deleu, and J. Lecourt, “Inhibition of Aminotransferases by Aminoethoxyvinylglycine Triggers a Nitrogen Limitation Condition and Deregulation of Histidine Homeostasis That Impact Root and Shoot Development and Nitrate Uptake,” Frontiers in Plant Science 10 (2019): 1387.

[367] E. Domínguez-Álvarez, B. Rácz, M. A. Marć, et al., “Selenium and Tellurium in the Development of Novel Small Molecules and Nanoparticles as Cancer Multidrug Resistance Reversal Agents,” Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy 63 (2022): 100844.

[368] S. M. Campos, S. Berlin, C. N. Krasner, et al., “A Phase I Study of AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies,” Cancer Chemotherapy and Pharmacology 89, no. 3 (2022): 423-430.

[369] G. Blackledge and A. S. Gefitinib, “Gefitinib (‘Iressa’, ZD1839) and New Epidermal Growth Factor Receptor Inhibitors,” British Journal of Cancer 90, no. 3 (2004): 566-572.

[370] A. Oprita, S. C. Baloi, G. A. Staicu, et al., “Updated Insights on EGFR Signaling Pathways in Glioma,” International Journal of Molecular Sciences 22, no. 2 (2021).

[371] Y. Yokoyama, T. M. Estok, and W. R. Sirpiglenastat, “Sirpiglenastat (DRP-104) Induces Antitumor Efficacy Through Direct, Broad Antagonism of Glutamine Metabolism and Stimulation of the Innate and Adaptive Immune Systems,” Molecular Cancer Therapeutics 21, no. 10 (2022): 1561-1572.

[372] A. Halama and K. Suhre, “Advancing Cancer Treatment by Targeting Glutamine Metabolism-A Roadmap,” Cancers 14, no. 3 (2022).

[373] C. Fulci, D. Rotili, A. De Luca, et al., “A New Nitrobenzoxadiazole-Based GSTP1-1 Inhibitor with a Previously Unheard of Mechanism of Action and High Stability,” Journal of Enzyme Inhibition and Medicinal Chemistry 32, no. 1 (2017): 240-247.

[374] H. Sha, S. Dong, C. Yu, et al., “In Vitro and in Vivo Efficacy of NBDHEX on Gefitinib-Resistant Human Non-Small Cell Lung Cancer,” Journal of Cancer 11, no. 24 (2020): 7216-7223.

[375] K. E. Carlström, E. Ewing, M. Granqvist, et al., “Therapeutic Efficacy of Dimethyl Fumarate in Relapsing-remitting Multiple Sclerosis Associates with ROS Pathway in Monocytes,” Nature Communications 10, no. 1 (2019): 3081.

[376] I. Kaluzki, T. Hailemariam-Jahn, M. Doll, et al., “Dimethylfumarate Inhibits Colorectal Carcinoma Cell Proliferation: Evidence for Cell Cycle Arrest, Apoptosis and Autophagy,” Cells 2019; 8(11).

[377] T. A. Yap, N. Daver, M. Mahendra, et al., “Complex I Inhibitor of Oxidative Phosphorylation in Advanced Solid Tumors and Acute Myeloid Leukemia: Phase I Trials,” Nature Medicine 29, no. 1 (2023): 115-126.

[378] K. Okunushi, T. Furihata, H. Morio, et al., “JPH203, a Newly Developed Anti-Cancer Drug, Shows a Preincubation Inhibitory Effect on L-type Amino Acid Transporter 1 Function,” Journal of Pharmacological Sciences 144, no. 1 (2020): 16-22.

[379] D. W. Yun, S. A. Lee, M. G. Park, et al., “JPH203, an L-Type Amino Acid Transporter 1-Selective Compound, Induces Apoptosis of YD-38 Human Oral Cancer Cells,” Journal of Pharmacological Sciences 124, no. 2 (2014): 208-217.

[380] M. J. Soth, K. Le, M. E. Di Francesco, et al., “Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties,” Journal of Medicinal Chemistry 63, no. 21 (2020): 12957-12977.

[381] V. B. Reddy, L. Boteju, A. Boteju, et al., “In Vitro and In Vivo Metabolism of a Novel Antimitochondrial Cancer Metabolism Agent, CPI-613, in Rat and Human,” Drug Metabolism and Disposition: the Biological Fate of Chemicals 50, no. 4 (2022): 361-373.

[382] K. C. Lee, R. Shorr, R. Rodriguez, C. Maturo, L. W. Boteju, and A. Sheldon, “Formation and Anti-tumor Activity of Uncommon in Vitro and in Vivo Metabolites of CPI-613, a Novel Anti-Tumor Compound That Selectively Alters Tumor Energy Metabolism,” Drug Metabolism Letters 5, no. 3 (2011): 163-182.

[383] S. Halford, G. J. Veal, S. R. Wedge, et al., “A Phase I Dose-escalation Study of AZD3965, an Oral Monocarboxylate Transporter 1 Inhibitor, in Patients With Advanced Cancer,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 29, no. 8 (2023): 1429-1439.

[384] N. Fei, S. Wen, R. Ramanathan, et al., “SMAD4 loss Is Associated With Response to Neoadjuvant Chemotherapy plus Hydroxychloroquine in Patients with Pancreatic Adenocarcinoma,” Clinical and Translational Science 14, no. 5 (2021): 1822-1829.

[385] K. Yen, J. Travins, F. Wang, et al., “AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations,” Cancer Discovery 7, no. 5 (2017): 478-493.

[386] K. D. Courtney, J. R. Infante, E. T. Lam, et al., “Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients with Previously Treated Advanced Clear Cell Renal Cell Carcinoma,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 36, no. 9 (2018): 867-874.

[387] W. Wang, R. Takimoto, F. Rastinejad, and W. S. El-Deiry, “Stabilization of p53 by CP-31398 Inhibits Ubiquitination Without Altering Phosphorylation at Serine 15 or 20 or MDM2 Binding,” Molecular and Cellular Biology 23, no. 6 (2003): 2171-2181.

[388] J. Hu, J. Cao, W. Topatana, et al., “Targeting Mutant p53 for Cancer Therapy: Direct and Indirect Strategies,” Journal of Hematology & Oncology 14, no. 1 (2021): 157.

[389] O. Hassin and M. Oren, “Drugging p53 in Cancer: One Protein, Many Targets,” Nature Reviews Drug Discovery 22, no. 2 (2023): 127-144.

[390] M. C. Ocaña, B. Martínez-Poveda, M. Marí-Beffa, A. R. Quesada, and M. Medina, “Fasentin Diminishes Endothelial Cell Proliferation, Differentiation and Invasion in a Glucose Metabolism-Independent Manner,” Scientific Reports 10, no. 1 (2020): 6132.

[391] D. Kraus, J. Reckenbeil, N. Veit, et al., “Targeting Glucose Transport and the NAD Pathway in Tumor Cells With STF-31: A Re-Evaluation,” Cellular Oncology 41, no. 5 (2018): 485-494.

[392] H. Yang, H. Wang, C. S. Shivalila, A. W. Cheng, L. Shi, and R. Jaenisch, “One-Step Generation of Mice Carrying Reporter and Conditional Alleles by CRISPR/Cas-Mediated Genome Engineering,” Cell 154, no. 6 (2013): 1370-1379.

[393] S. W. Cho, S. Kim, Y. Kim, et al., “Analysis of off-Target Effects of CRISPR/Cas-Derived RNA-Guided Endonucleases and Nickases,” Genome Research 24, no. 1 (2014): 132-141.

[394] S. Q. Tsai and J. K. Joung, “Defining and Improving the Genome-Wide Specificities of CRISPR-Cas9 Nucleases,” Nature Reviews Genetics 17, no. 5 (2016): 300-312.

[395] A. Fire, S. Xu, M. K. Montgomery, S. A. Kostas, S. E. Driver, and C. C. Mello, “Potent and Specific Genetic Interference by Double-Stranded RNA in Caenorhabditis elegans,” Nature 391, no. 6669 (1998): 806-811.

[396] S. M. Elbashir, J. Harborth, W. Lendeckel, A. Yalcin, K. Weber, and T. Tuschl, “Duplexes of 21-Nucleotide RNAs Mediate RNA Interference in Cultured Mammalian Cells,” Nature 411, no. 6836 (2001): 494-498.

[397] J. Burchard, A. L. Jackson, V. Malkov, et al., “MicroRNA-Like off-Target Transcript Regulation by siRNAs is Species Specific,” Rna 15, no. 2 (2009): 308-315.

[398] J. Gao, C. Ding, J. Zhou, et al., “Propofol Suppresses Lung Cancer Tumorigenesis by Modulating the Circ-ERBB2/miR-7-5p/FOXM1 Axis,” Thoracic Cancer 12, no. 6 (2021): 824-834.

[399] H. Zhao, H. Wei, J. He, et al., “Propofol Disrupts Cell Carcinogenesis and Aerobic Glycolysis by Regulating circTADA2A/miR-455-3p/FOXM1 Axis in Lung Cancer,” Cell Cycle (Georgetown, Tex) 19, no. 19 (2020): 2538-2552.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.